Gregory Weinhoff Sells 73,196 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Gregory Weinhoff sold 73,196 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the transaction, the insider owned 65,925 shares of the company’s stock, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Centessa Pharmaceuticals Trading Down 3.3%

Shares of NASDAQ:CNTA traded down $0.89 during trading on Friday, reaching $26.33. The stock had a trading volume of 1,362,238 shares, compared to its average volume of 1,141,428. The firm’s fifty day moving average is $24.69 and its 200 day moving average is $24.24. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $9.60 and a 52 week high of $30.58. The stock has a market cap of $3.85 billion, a price-to-earnings ratio of -14.39 and a beta of 1.55.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth about $80,000. T. Rowe Price Investment Management Inc. increased its position in Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after buying an additional 1,516 shares in the last quarter. Coastal Bridge Advisors LLC raised its stake in Centessa Pharmaceuticals by 7.1% during the 4th quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock worth $351,000 after buying an additional 931 shares during the period. XTX Topco Ltd acquired a new position in Centessa Pharmaceuticals during the 4th quarter worth approximately $1,978,000. Finally, Voloridge Investment Management LLC bought a new position in Centessa Pharmaceuticals in the fourth quarter worth approximately $8,710,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CNTA. Oppenheimer upped their price target on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Wolfe Research initiated coverage on Centessa Pharmaceuticals in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $40.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. B. Riley Financial raised their target price on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Finally, Wells Fargo & Company lifted their target price on Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Centessa Pharmaceuticals has an average rating of “Buy” and a consensus target price of $39.80.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.